Skip to main content

Table 1 Summary of the immune-related analysis

From: Melan-A/MART-1 immunity in a EWS-ATF1 translocated clear cell sarcoma patient treated with sunitinib: a case report

Date   Immune-related analysis
December 2010 (Dec-2010) biopsy IHC: MART-1/Melan-A +; S-100 +; gp100/HMB-45 +  
November 2011 surgery IHC: MART-1/Melan-A +; S-100 +; gp100/HMB-45 +  
January 2012 (Jan-2012) sunitinib   Immunological monitoring:
April 2012 surgery IHC: MART-1/Melan-A -; S-100 +; gp100/HMB-45 +; CD3 +; CD8 + • Frequency of immunosuppressive cells and CD3+ T cell function (Figure 4)
May 2012/April 2013 sunitinib*   • Presence of Melan-A/MART-1 specific CD8+ T cells (Figure 3)
  1. Abbreviations: IHC, immunohistochemistry.
  2. Note: *stopped many times due to toxicity with evidence of disease progression following treatment interruption and new response after restoring treatment.